Creative Planning’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.83M Sell
84,188
-11,029
-12% -$213K ﹤0.01% 1965
2025
Q4
$2.05M Buy
95,217
+58,139
+157% +$1.23M ﹤0.01% 1714
2025
Q3
$714K Buy
+37,078
New +$661K ﹤0.01% 2417
2025
Q2
Sell
-7,986
Closed -$510K 3787
2025
Q1
$510K Sell
7,986
-882
-10% -$92.8K ﹤0.01% 2266
2024
Q4
$1.08M Buy
8,868
+1,191
+16% +$146K ﹤0.01% 1595
2024
Q3
$959K Sell
7,677
-260
-3% -$35.9K ﹤0.01% 1543
2024
Q2
$1.25M Buy
7,937
+829
+12% +$106K ﹤0.01% 1261
2024
Q1
$920K Buy
7,108
+1,104
+18% +$135K ﹤0.01% 1392
2023
Q4
$579K Sell
6,004
-17,159
-74% -$1.65M ﹤0.01% 1602
2023
Q3
$2.8M Buy
23,163
+665
+3% +$75.2K ﹤0.01% 712
2023
Q2
$2.58M Buy
22,498
+162
+0.7% +$20.9K ﹤0.01% 717
2023
Q1
$3.08M Buy
22,336
+395
+2% +$51.2K ﹤0.01% 635
2022
Q4
$2.84M Buy
21,941
+298
+1% +$34.5K ﹤0.01% 638
2022
Q3
$2.39M Sell
21,643
-472
-2% -$47.6K ﹤0.01% 639
2022
Q2
$1.66M Sell
22,115
-1
-0% -$74 ﹤0.01% 780
2022
Q1
$1.73M Sell
22,116
-5
-0% -$383 ﹤0.01% 761
2021
Q4
$1.99M Sell
22,121
-1,253
-5% -$107K ﹤0.01% 690
2021
Q3
$2.16M Sell
23,374
-3,588
-13% -$276K ﹤0.01% 661
2021
Q2
$2.1M Sell
26,962
-5,615
-17% -$426K ﹤0.01% 666
2021
Q1
$2.43M Sell
32,577
-2,806
-8% -$259K ﹤0.01% 644
2020
Q4
$6.03M Buy
35,383
+753
+2% +$112K 0.01% 335
2020
Q3
$4.86M Buy
34,630
+6,823
+25% +$1.04M 0.01% 315
2020
Q2
$4.46M Buy
27,807
+420
+2% +$57.2K 0.01% 302
2020
Q1
$2.68M Sell
27,387
-32,501
-54% -$3.72M 0.01% 355
2019
Q4
$7.73M Buy
59,888
+7,563
+14% +$763K 0.02% 234
2019
Q3
$3.94M Sell
52,325
-57,465
-52% -$6.79M 0.01% 335
2019
Q2
$16.7M Sell
109,790
-19,900
-15% -$2.42M 0.06% 128
2019
Q1
$15.5M Buy
129,690
+59,487
+85% +$7.65M 0.06% 125
2018
Q4
$7.66M Sell
70,203
-9,224
-12% -$1.15M 0.03% 182
2018
Q3
$12.8M Buy
79,427
+8,280
+12% +$1.13M 0.05% 140
2018
Q2
$9.4M Sell
71,147
-15,703
-18% -$1.48M 0.04% 162
2018
Q1
$6.43M Sell
86,850
-11,833
-12% -$789K 0.03% 201
2017
Q4
$5.49M Sell
98,683
-5,073
-5% -$269K 0.02% 224
2017
Q3
$4.71M Sell
103,756
-3,344
-3% -$134K 0.02% 251
2017
Q2
$3.61M Sell
107,100
-4,025
-4% -$131K 0.02% 280
2017
Q1
$3.29M Buy
111,125
+11,800
+12% +$365K 0.02% 291
2016
Q4
$2.72M Buy
99,325
+53,625
+117% +$2.15M 0.02% 321
2016
Q3
$2.81M Sell
45,700
-20,000
-30% -$605K 0.02% 306
2016
Q2
$1.25M Buy
65,700
+11,550
+21% +$214K 0.01% 456
2016
Q1
$1.06M Buy
54,150
+1,200
+2% +$21K 0.01% 487
2015
Q4
$2.04M Buy
52,950
+25,900
+96% +$840K 0.02% 307
2015
Q3
$869K Sell
27,050
-1,500
-5% -$50.9K 0.01% 519
2015
Q2
$869K Buy
28,550
+6,500
+29% +$133K 0.01% 510
2015
Q1
$293K Buy
22,050
+4,000
+22% +$53.3K ﹤0.01% 1003
2014
Q4
$261K Buy
18,050
+7,800
+76% +$132K ﹤0.01% 998
2014
Q3
$216K Buy
10,250
+4,400
+75% +$99.3K ﹤0.01% 1020
2014
Q2
$174K Buy
5,850
+50
+0.9% +$1.58K ﹤0.01% 1104
2014
Q1
$139K Buy
5,800
+5,034
+657% +$128K ﹤0.01% 1192
2013
Q4
$16K Buy
766
+700
+1,061% +$20.8K ﹤0.01% 2323
2013
Q3
$3K Hold
66
﹤0.01% 2911
2013
Q2
$3K Buy
+66
New +$2.36K ﹤0.01% 2738

Other funds holding SRPT

Creative Planning's SRPT Position: Q1 2026 in Review

Creative Planning reduced its Sarepta Therapeutics (SRPT) stake by 12% in Q1 2026, selling an estimated $213K and leaving 84,188 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

Creative Planning first reported a position in SRPT in Q2 2013 and has held it in 51 quarters since. The position peaked at $16.7M in Q2 2019. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Creative Planning held 84,188 shares of Sarepta Therapeutics worth $1.83M as of Q1 2026.
  • Creative Planning sold 11,029 Sarepta Therapeutics shares in Q1 2026, an estimated $213K.
  • Sarepta Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1965 holding.
  • Creative Planning first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • Creative Planning's Sarepta Therapeutics position peaked at $16.7M in Q2 2019.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.